Gabelli Dividend & Income Trust (NYSE:GDV) trades near $29 and pays a $0.15 monthly distribution, up from $0.11 per month in 2024 to $0.14 in 2025 to $0.15 starting January 2026. At…
One of Wall Street’s top firms just made the bull case for AbbVie (NYSE:ABBV | ABBV Price Prediction) stock, initiating coverage with a Buy rating and a $262 price target. Canaccord calls…
David Moadel AbbVie (NYSE:ABBV | ABBV Price Prediction) has attracted persistent buying interest, and every pullback has drawn in value-focused investors. The stock is down 7.03% year-to-date as of mid-April 2026, sitting at $208.99,…
Vandita Jadeja AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record net sales with revenue up 10% year over year, powered by a…
AbbVie (NYSE:ABBV | ABBV Price Prediction) stock has pulled back 12% over the past month, sliding to around $204. JPMorgan isn’t running from that weakness — it’s calling it a buying opportunity,…
Pharmaceutical companies AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth-quarter earnings in early February, revealing two very different pharmaceutical stories. AbbVie is riding a post-Humira reinvention, while Pfizer…
With inflation back in the economic picture, simply getting a dependable income stream may not be the best strategy for Boomer and Gen X retirees. Without some degree of growth, portfolios built…
Retirees and income-focused investors have long used Vanguard Value ETF (NYSEARCA:VTV) as a core portfolio anchor, drawn to its dividend income, lower volatility relative to growth funds, and near-zero cost structure. When…
Healthcare spending doesn’t stop during recessions. That structural reality is the core argument for owning Vanguard Health Care ETF (NYSEARCA:VHT), a pure-play sector fund that has quietly compounded wealth for long-term investors…
A 1.5% yield sounds unimpressive until you realize the dividend check doubles roughly every seven years. That is the premise behind the Vanguard Dividend Appreciation ETF (NYSEARCA:VIG): skip the high-yield traps and…
Growth investing has had a choppy start to 2026. The major growth benchmarks are down in the low single digits year-to-date, and some of the biggest names in tech have pulled back…
JPMorgan Dividend Leaders ETF (NYSEARCA:JDIV) launched in September 2024 with an appealing premise: a curated portfolio of global dividend leaders. The name implies income. The reality is a 1.59% yield at a…
At 60 with $500,000 saved, you are closer to a workable retirement income than most people realize. The math is concrete, the variables are manageable, and the biggest decision you will make…
Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC’s Halftime Report this week about large-cap biotech: “These are growth stocks where you don’t have to worry about disruption.…
DGRO has raised its annual dividend every single year since inception, through a pandemic, a rate-hiking cycle, and multiple bouts of market panic. For retirees building an income portfolio, that consistency matters…
